Kornimate/medical-research-clean huggingface dataset:
society for pediatric anesthesia improvement network- anterior cruciate ligament reconstruction outcomes project

Conditions: Anterior Cruciate Ligament Injuries

Summary: the primary objective is to create a multicenter registry which captures information relating to the perioperative anesthesia course and management of children undergoing anterior cruciate ligament reconstruction and to examine practice patterns and incidence of complications. data from any single institution involved in this registry will be used for local safety and quality improvement efforts. in addition data from each institution can be compared to the information from the entire group of institutions participating in the project, thus providing a measure for comparison with national practice. the aggregate multi-institutional data set will be used to develop quality benchmarks for national safety and quality improvement efforts and best practice recommendation. we believe that this registry can also demonstrate how web based data collection can be used to evaluate clinical anesthesia outcomes for surgeries with a low incidence of critical events but with significant variability in medical management.

this multi institutional registry will capture data relating to perioperative practices and complications, some of which may be relatively infrequent. the goal of this group is to create this registry to be used for local safety and quality improvement and multi-center benchmarking in this population. reports generated from the registry will provide individual institutions with comparative data showing how their site performs compared to composite averages from all participating sites. queries of the composite data set may allow for identification of factors associated with improved outcomes in this population. future queries of the data-base for research purposes will require approval of the participating members of spain.

Eligibility criteria:
inclusion criteria: * males and females ages 12 years to 17.5 years * patients undergoing scheduled surgical procedures on the anterior cruciate ligament construction surgery in a hospital setting or surgical day center. exclusion criteria: * incarcerated subjects * non-english speaking families and subjects
physiotherapy on pneumonia in childrens

Conditions: Pneumonia

Summary: the children's susceptibility to respiratory problems is due to their anatomical and physiological characteristics; therefore, children with more severe clinical conditions may undergo invasive mechanical ventilation (imv). however, its prolonged use favors tracheal injury, barotrauma and / or volutrauma, decreased cardiac output and oxygen toxicity, and especially the accumulation of respiratory secretions due to ineffective cough due to non-closure of the glottis and damage in the transport of mucus by the presence of the tracheal tube. thus, triggering the development of mechanical ventilation-associated pneumonia (vap), which is defined as a pulmonary infection that arises 48 to 72 hours after endotracheal intubation and the institution of invasive mechanical ventilation. as a consequence, respiratory work is performed by imv, reducing the work exerted by spontaneous ventilation, causing neuromuscular disorders after 5 to 7 days of imv, changes in muscle mechanics, reducing the capacity of the diaphragm to generate force, thus contributing to changes in modulation autonomic heart rate, changes in muscular trophism, generating physical deconditioning due to weakness and, finally, an increase in the length of hospitalization and immobilism. from this perspective, early mobilization emerges as a rehabilitation mechanism to improve muscle strength and joint mobility, as well as to improve lung function and respiratory system performance, as well as improved autonomic heart rate modulation. it can facilitate the weaning of imv, reducing hospitalization time and promoting quality of life after discharge.

we will select 40 volunteers of both sexes and between the ages of 1 and 8 years, with clinical diagnosis of vap hospitalized in an intensive care unit, which will be submitted, together with the hospital protocol, the protocol of early mobilization. for these patients will be performed physical therapy evaluation in the pre-protocol period, on the second and fourth day of application of the protocol and 1 week at the end of the proposed protocol. for statistical analysis will be compared the pre and post-treatment data found in the evaluations and tabulated in a microsoft excel worksheet. biostat 5.2 software will be used to analyze the results, and the choice of tests for this will depend on the types of distributions found and the homogeneity of the variables.

Eligibility criteria:
inclusion criteria: * patients on invasive or non-invasive mechanical ventilation for less than 96 hours * with pneumonia due to invasive mechanical ventilation, * aged between 1 year and 8 years exclusion criteria: * severe respiratory failure * active bleeding * acute cerebral disorder * presence of orthopedic contraindications (bone fractures, dislocations, subluxations, postoperative, unstable spine) * neurological impairment with minimal functionality * neuromuscular disease

Keywords: pneumonia, ventilator-associated mechanical ventilation physical therapy
mfolxox6 versus folfiri for colorectal patients recurrence after oxaplatin based adjuvant chemotherapy

Conditions: Metastatic Colorectal Cancer

Summary: a multicenter,open,prospective randomized controlled trial;11 study center in china; plan to enroll 328 patients（ power analysis and sample size ）.comparing folfiri with mfolfox6,superiority design.investigate difference pfs,orr,r0 resection rate,os ,qol and safety from two regimens stratification factors : analyzing patients recurrence within 6-12months,and 12-18months .obtain definite chemotherapy regimen shift opportunity for patients recurrence/metastasis after adjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: 18-75 years，male or female colorectal adenocarcinoma accepting more than 4 cycles oxaplatin based adjuvant chemotherapy after radical operation reccurrence in 6-18 months after adjuvant chemotherapy at least one assessable lesions no intestinal obstruction ecog 0-1 estimated survival≥ 3 months cbc：wbc\>4×109/l，plt\>80×109/l，hb\>90g/l， liver function：alt or ast \< 2× normal maximum value， t-bile\<1.5× normal maximum value without hepatic metastatic， alt or ast \< 5× normal maximum value， t-bile\<1.5× normal maximum value with hepatic metastatic cr\<1.8mg/dl signed informed consent exclusion criteria: locally resectable lesions grade 2-4 oxaliplatin induced neurotoxicity arrhythmias，coronary heart disease，or congestive heart failure（nyha≥grade 2） requiring treatment poorly controlled hypertension hiv infected or active hbv or hcv infected active serious infection cachexia or organ function decompensation multiple primary carcinoma except carcinoma in situ of skin and cervix participate in other clinical studies at the same time serious heart or brain disease drug abuse or other serious psychosocial diseases suspected trial drug allergy other factors affecting patient safety and compliance pregnant or lactating women，or fertility without adequate contraceptive measures

Keywords: metastatic colorectal cancer completion of adjuvant therapy first line chemotherapy
artiaid® plus for knee osteoarthritis: a post-market study

Conditions: Hyaluronic Acid

Summary: the goal of this open-label, post-market clinical follow-up study is to demonstrate the safety and performance of artiaid® plus intra-articular injection in patients with knee osteoarthritis(oa). the main questions it aims to answer are: * the safety profile of artiaid® plus; * the clinical performance of artiaid® plus, such as pain relief and satisfaction of treatment. participants will receive weekly injections of artiaid® plus for 3 weeks and be follow-up for 26 weeks.

an open-label study will be performed in single center to monitor about 60 patients with knee osteoarthritis(oa), each treated with 3 injections of artiaid® plus 1.5% (maxigen biotech inc., taiwan). follow-up visits will be at 4 weeks, 12 weeks(a telephone contact by the investigator) and 26 weeks after the injections. the primary endpoint of this study is to monitor the adverse events after injecting artiaid® plus. the secondary endpoints of this study are demonstrating the clinical performance of artiaid® plus, such as resting knee pain and satisfaction of treatment by using the visual analog scale (vas). analysis of variance (anova) will be applied to the clinical data and t-test will be used to test for the differences between baseline and each visit. the paired student t-test was used to analyze variations in each group over a period of time. statistical significance was established at p \< 0.05.

Eligibility criteria:
inclusion criteria: * subjects aged older than 40 years old. * able to sign informed consent prior to the study. * subjects have kellgren-lawrence (kl) grade 2 to 3 knee osteoarthritis. * subjects have failed to respond adequately to conservative non-pharmacological therapy. * plasma pregnancy test at screening visit must be negative for fertile female subjects. * subjects in stable progress of disease as judged by the investigator. exclusion criteria: * subjects with known hypersensitivity to hyaluronate preparations. * subjects with infections or skin diseases in the area of the injection site. * pregnancy or breast-feeding woman. * significant drug, alcohol abuse. * joining any clinical trial within 3 months prior to dosing. * subjects have traveled abroad within 3 months prior to the screening visit.

Keywords: viscosupplements osteoarthritis, knee injections, intra-articular
evaluating the efficacy of valsalva's maneuver and music therapy on peripheral venous cannulation

Conditions: Cannulation,Pain

Summary: evaluating the efficacy of valsalva's maneuver and music therapy on peripheral venous cannulation pain and anxiety

one hundred and fifty patients undergoing surgery were randomized to apply valsalva's maneuver (the valsalva group) and music therapy(the music group) and a placebo (the control group) during peripheral venous cannulation (pvc). the patients' pain, anxiety, and satisfaction scores will be measured.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologist (asa) physical status 1 and 2, between the ages of 18 and 65, were scheduled for elective surgery exclusion criteria: * patients with a history of anxiety disorders or hearing problem and preoperative pain.
pet imaging of 68ga-her2-affibody in tumors with high her2 expression

Conditions: Neoplasms

Summary: this project uses her2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68ga-her2-affibody in the expression status of her2, aiming to provide a new imaging method for the determination of her2 status in breast cancer at the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

this project uses her2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68ga-her2-affibody in the expression status of her2 in whole body cancer lesions, aiming to provide a new imaging method for the determination of her2 status in breast cancer and supplement more overall information that is difficult to obtain by traditional core needle biopsy. at the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

Eligibility criteria:
inclusion criteria: - patients with confirmed or suspected cancer; signed written informed consent exclusion criteria: -

Keywords: 68ga-her2-affibody pet/ct neoplasms
benchmarks in elective laparoscopic cholecystectomy

Conditions: Gall Stone; Gallbladder Inflammation; Gall Bladder Pain; Gallstone; Gall Stones (& [Calculus - Gall Bladder])

Summary: the aim of this observational cohort study is to define peri- and postoperative reference values for elective laparoscopic cholecystectomy, using the achievable benchmarks of care methodology (abc™). another aim is to develop adjusted reference values for groups with a risk factor of severe postoperative complications. the over-arching aim is to inspire quality improvement initiatives.

the data source is the swedish patient registry gallriks, a prospective quality registry for gallbladder surgery and endoscopic retrograde cholangio-pancreatography (ercp). the time frame will be 2015-2023. register variables related to surgical quality will be analyzed, such as postoperative complications, perioperative adverse events, surgical duration and length of stay. the study will analyze data for the time of surgery and up to 30 days afterwards. since the data is not yet available to the researchers the number of enrolled study participants can not be specified with certitude; therefore an anticipated number is given.

Eligibility criteria:
inclusion criteria: * adults ≥ 18 years of age * laparoscopic primary cholecystectomy exclusion criteria: * patients with current acute cholecystitis, pancreatitis or cholangitis * cholecystectomy due to malignancy * other organ surgery performed at the same occasion * previous upper gastrointestinal surgery * single port access * robotic surgery * no data concerning surgical intervention

Keywords: laparoscopic cholecystectomy benchmarking surgical outcomes reference values quality improvement risk factors of surgical complications
a study comparing obinutuzumab and bgb-3111 versus obinutuzumab alone in treating r/r follicular lymphoma

Conditions: Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

Summary: he purpose of the study is to evaluate the efficacy, safety, and tolerability bgb-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-hodgkin follicular lymphoma.


Eligibility criteria:
key inclusion criteria: 1. histologically confirmed diagnosis of b-cell follicular lymphoma 2. ≥2 prior systemic treatments for follicular lymphoma. 3. previously received an anti-cd20 antibody and an appropriate alkylator-based combination therapy. 4. disease progression after completion of most recent therapy or refractory disease. 5. presence of measurable disease. 6. availability of archival tissue confirming diagnosis. 7. eastern cooperative oncology group (ecog) performance status of 0,1 or 2. 8. adequate renal and hepatic function. key exclusion criteria: 1. prior exposure to a bruton's tyrosine kinase (btk) inhibitor. 2. known central nervous system involvement by leukemia or lymphoma. 3. evidence of transformation from follicular lymphoma to other aggressive histology. 4. allogeneic hematopoietic stem cell transplantation within 12 months of enrollment 5. prior malignancy within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix of breast, or localized gleason score 6 prostate cancer. 6. clinically significant cardiovascular disease. 7. major surgery ≤ 4 weeks prior to start of study treatment. 8. active fungal, bacterial or viral infection requiring systemic treatment. 9. history of severe bleeding disorder. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: relapsed/refractory follicular non-hodgkin lymphoma
effect of combined red and near infrared light-emitting diode (led) therapy on tissue regeneration post laser treatment

Conditions: Wound Heal

Summary: the purpose of this study is to evaluate the effect of light therapy on wound healing after laser treatment.

this study sets out to evaluate the effect of a combination of near infrared (830 nm) red (633 nm) and blue (465nm) light-emitting diode (led) therapy on wound healing after laser application.

Eligibility criteria:
inclusion criteria: adults aged 18 years or older with no active cutaneous disease on bilateral ventral biceps, close to the axilla. subjects shall have given written informed consent for both the led therapy and for clinical photography. exclusion criteria: patients will be excluded if any of the exclusion criteria applies * subjects refuse to give informed consent for either the phototherapy or the clinical photography. * subjects have previous photosensitivity problems (solar urticaria, etc.). * subjects are taking any systemic drug or applying any topical drug with known photosensitizing properties. * subjects taking any systemic drug with known immunosuppressant properties. * subjects applying any medications to the research site (inner biceps, close to the axilla). * subjects have medical or psychosocial conditions associated with a risk of poor protocol compliance. * subjects are smokers or have smoked within the last 30 days prior to the trial. * subjects have epilepsy or a history of seizures * subjects currently taking cortisone injections or any other kind of steroid injections(s) * subjects with known cancer tumor in the treatment area or metastasis
effect of platelet-rich plasma biomembrane on enhancing bone regeneration following endodontic surgery

Conditions: Endodontic Disease

Summary: this study was conducted to evaluate clinical and radiographical outcome of using a standardized platelet-rich plasma (prp) biomembrane following endodontic surgery and its correlation with the growth factors content in this concentrate.

15 healthy patients of both genders, between 20 and 45 years of age, presenting with 22 anterior/premolar teeth in need of endodontic surgery were recruited. teeth presented with failed non-surgical root canal therapy and periapical radiolucency of ≥ 1cm in size. patients were randomly divided following surgery into two groups, with 11 teeth each.

Eligibility criteria:
inclusion criteria: 1. healthy patients. 2. selected tooth with previous root canal therapy failure and in need of endodontic surgery. 3. existence of a periapical radiographic lesion surrounding the root canal treated tooth, of size ≥ 1 cm. 4. healthy periodontal condition (probing depth, mobility \& epithelial attachment level are all within normal range). exclusion criteria: 1. leaking coronal restoration. 2. periodontal ligament breakdown and presence of apicomarginal defects.
validation of the russian version of coma recovery scale-revised (crs-r)

Conditions: Consciousness Disorders

Summary: the purpose of this study is to validate russian version of coma recovery scale - revised and to assess its psychometric properties.

there is a need of validated scale for correct assessment for patients with disorders of consciousness (doc) in russia. one of the most detailed scales that provides robust results in these patients is the coma recovery scale - revised (crs-r). the validated russian version of crs-r will be very helpful in clinical work and scientific research for making correct assessment of patients status and its changes over time in russia and russian-speaking countries. the purpose of this study is to validate russian version of crs-r and to assess its psychometric properties. the first step of the study was to perform translation of crs-r from english into russian according to the validation protocol: 1. double direct translation by independent translators; 2. combination of two russian translations; 3. reverse translation by native english speaker. final russian version and back-translated version of the scale were approved by the original author, dr. j. giacino. he approved the original validation study protocol as well. to validate russian version of crs-r and to assess its psychometric properties the investigators will perform an observational study on 60 adults with disorders of consciousness of different etiology on different period of recovery after coma. it is planned to include patients with various states of consciousness (e.g., vegetative state, minimally conscious state "minus" and minimally conscious state "plus") in balanced proportions. every patient will be examined by two independent researchers on the same day. the patients will be examined twice with a week interval between examinations for evaluation of sensitivity of crs-r. test-retest reliability will be applied to investigate interrater reliability. this method will be applied as well to assess the consistency of patients' scores over time. the internal consistency of the test will be investigated by inter-rater method. for this item two researchers will conduct patient assessment with crs-r on the same day with a small period of time between the examinations. content validity of the test will be used for assessment of validity of crs-r. it will be performed with expert evaluation of the content of crs-r by the investigators. сriterion validity will be examined by assessing the correlations of crs-r with the scales of other questionnaires with proven high psychometric properties for consciousness disorders: the glasgow coma scale and full outline of unresponsiveness (four) score.

Eligibility criteria:
inclusion criteria: * adults recovering after coma in any period (persistent, permanent); * vegetative state or minimal conscious state; * locked-in syndrome. exclusion criteria: * coma, brain death.

Keywords: disorders of consciousness validation studies coma vegetative state
acro biocornea clinical trial in taiwan

Conditions: Corneal Ulcer

Summary: the goal of this clinical trial is to investigate the safety and clinical performance of abccolla collagen ophthalmic matrix used for anterior lamellar keratoplasty in patients suffering from corneal ulcer. participants will undergo keratoplasty using the investigational product and be followed up for 24-week observation (total of 10 times).


Eligibility criteria:
1. inclusion criteria: 1. male or female from 20 to 80 years old 2. subject who has been diagnosed with corneal ulcer 3. the depth or the size of the ulcer increases or increased anterior chamber inflammation after treatment (clinic, hospitalization, or others...) 4. the corneal ulcer affects corneal stroma depth to 1/3 and infiltrates \>2 mm diameter, detected by oct 5. best corrected vision acuity \< 0.05 6. subject who signs the informed consent form (icf), and agrees to complete the treatment and follow-up 2. exclusion criteria: 1. accepted keratoplasty 2. has a corneal perforation and expects to have vision 3. has a severe dry eye 4. experience s incomplete eyelid closure 5. h as liver function (alt and ast) tests with the score as twofold or greater than that of the normal 6. has renal function (cr) levels greater than normal two folders 7. has serum protein 10% low than normal 8. has severe cardiovascular and cerebral vascular disease 9. subject with uncontrolled diabetes 10. subject with current malignancy 11. known to be allergic to collagen 12. has a systemic collagen connective tissue disease 13. has a constitution prone to severe allergic reactions 14. use s anticoagulants 5 days before studying keratoplasty 15. use s injectable nsaid 3 days before studying keratoplasty 16. cannot accept investigated material due to religious or cultural reason 17. pregnant or breastfeeding women or childbearing-age women who plan to get pregnant 18. participation in any drug or medical device clinical trial within 30 days prior to signing the informed consent form; 19. not being considered suitable for this study by the investigator